Cystic Fibrosis (CF) Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of AIR-DNase When Administered by Inhalation to Healthy Adult Subjects
Verified date | April 2016 |
Source | Protalix |
Contact | n/a |
Is FDA regulated | No |
Health authority | Israel: Ministry of Health |
Study type | Interventional |
This study will be performed to assess the safety, tolerability and PK of escalating inhaled
AIR-DNase doses administered as a single dose followed by multiple doses for 5 consecutive
days in healthy subjects.
A thorough review of safety data will be conducted after completion of each dose level per
subject and prior to both, moving to the next dose level in Part 1 and commencement of the
multiple dose Part 2.
Status | Completed |
Enrollment | 18 |
Est. completion date | February 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: 1. Subject who understands the study procedures and provides written informed consent to participate in the study. 2. Healthy, male, 18-55 years of age, inclusive 3. Non smoker, by declaration, for at least 6 months prior to screening 4. Body mass index (BMI) = 18.5 and = 29.0 kg/m2 at screening. 5. Healthy individual with no clinically significant findings in: medical history, physical examination, laboratory profiles , vital signs, 12-lead ECG 6. Spirometry results within normal ranges. 7. A subject, whose female co-partner is of child-bearing potential, must agree to use two medically acceptable methods of contraception throughout the study. Exclusion Criteria: 1. History of asthma, any chronic pulmonary disease, recurrent pneumonia, allergic rhinitis. 2. History of any illness or medical condition (including psychiatric) that might confound the results of the study or poses an additional risk to the subject by his participation in the study. 3. Any acute illness (e.g. acute infection) within 48 hours prior to the study drug administration, which is considered of significance by the Investigator. 4. Known contraindication, hypersensitivity and/or allergy to any drug. 5. History of adverse reactions during aerosol delivery of any medicinal product. 6. History or presence of alcoholism or drug abuse within the past 2 years prior to screening. 7. Positive urine drug of abuse test result prior to first dosing. 8. Positive breath alcohol test on admission to the CRC prior to first dosing. 9. Positive results at screening for HIV, HBsAg, or HCV Ab. 10. Sitting blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg at screening. 11. Sitting heart rate is lower than 45 beats per minute (bpm) or higher than 99 bpm at screening. 12. Use of any prescription or over-the-counter medications, including vitamins, herbal, or dietary supplements within 14 days prior to dosing. Paracetamol, up to 2g /day is allowed up to 24 hours prior to dosing. 13. Donation of blood within 90 days prior to dosing. 14. Donation of bone marrow within the last 6 months prior to dosing. 15. Participation in another clinical trial within 90 days prior to dosing in which a study drug has been administered. 16. Subject is mentally or legally incapacitated or has significant emotional problems or is unable to communicate well with the investigators and CRC staff (i.e., language problem, poor mental development or impaired cerebral function). |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Israel | Sourasky Medical Center | Tel Aviv |
Lead Sponsor | Collaborator |
---|---|
Protalix |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adverse events following inhaled single dose (SD) of AIR-DNase | Adverse events from subject reporting or other assessments | 10 days | Yes |
Primary | Adverse events following inhaled multiple doses (MD) of AIR-DNase | Adverse events from subject reporting or other assessments | 14 days | Yes |
Secondary | Area under the curve | AIR DNase concentrations measured at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, and 4 hours | 4 hours | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04853368 -
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis
|
Phase 2 | |
Terminated |
NCT03234387 -
A CFit Study - Baseline
|
||
Completed |
NCT03445793 -
: TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)
|
||
Completed |
NCT02778750 -
Evaluation Of The Pan-microbiome and Host Immune Response in CF
|
||
Completed |
NCT00677365 -
Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
|
Phase 2 | |
Terminated |
NCT03597347 -
Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection
|
Phase 2 | |
Recruiting |
NCT05818319 -
Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in Urine After a Short Pause of Therapy
|
N/A | |
Completed |
NCT04375878 -
OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis
|
Phase 2 | |
Withdrawn |
NCT01951833 -
Long Term Significance (Survival) of LCI in Patients With Cystic Fibrosis
|
N/A | |
Completed |
NCT03746483 -
OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
|
Phase 2 | |
Completed |
NCT02163681 -
MRI for Non-Invasive Imaging in Neonates and Children
|
N/A | |
Completed |
NCT02036879 -
Gender Disparity and Hormones in Cystic Fibrosis
|
Early Phase 1 | |
Recruiting |
NCT01851642 -
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
|